Mainstream

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Oruka jumps as lead drug outperforms AbbVie’s Skyrizi in early-stage trial

Post Contentorka, abbvRead More

You might also be interested in reading Bitcoin Price Dumped To $66K As Bears Gain Strength, $64K Next?.

September 17, 2025
In Mainstream